Surgical resection for small hepatocellular carcinoma. 1996

I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
First Department of Surgery, University of Tokyo, Japan.

BACKGROUND Surgical resection for hepatocellular carcinoma (HCC) can be curative in selected patients, particularly in those with a solitary small HCC (s-sHCC; 2 cm or less in diameter). However, even these patients often have a risk of tumor recurrence or death from underlying liver dysfunction. Therefore it is important to determine which clinicopathologic features are related to the long-term prognosis after resection of s-sHCC. METHODS Fifty patients with s-sHCC underwent partial hepatectomy at our department between 1977 and 1992. Six (12%) died of liver failure in hospital after operation. Eight clinicopathologic features were examined in the remaining 44 patients with regard to their long-term prognosis by use of univariate and multivariate analyses. RESULTS The 1-, 3-, and 5-year survival rates were 90%, 75%, and 53%, respectively. The corresponding disease-free survival rates were 80%, 53%, and 30%, respectively. None of the following parameters was significantly related to survival rate or disease-free survival rate: presence of vascular invasion or capsular formation, the distance of free surgical margin (1 cm or more or not), serum alpha-fetoprotein level, positive hepatitis B surface antigen, and preoperative transarterial embolization. Complicated liver function was the only significant factor related to survival rate and disease-free survival rate. CONCLUSIONS A good hepatic reserve is an important factor in treating patients with s-sHCC by surgical resection, even for a long-term prognosis. Liver transplantation should be considered for patients with severe cirrhosis and s-sHCC, even though a curative resection might be possible.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006498 Hepatectomy Excision of all or part of the liver. (Dorland, 28th ed) Hepatectomies
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
October 2023, Liver cancer,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
June 2023, Liver cancer,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
October 2007, Journal of gastroenterology and hepatology,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
October 2001, Nihon rinsho. Japanese journal of clinical medicine,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
January 1988, Annals of the Academy of Medicine, Singapore,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
January 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
January 2001, Cancer treatment and research,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
April 1990, Hepato-gastroenterology,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
January 1993, Acta chirurgica Belgica,
I Nagashima, and C Hamada, and K Naruse, and T Osada, and T Nagao, and N Kawano, and T Muto
January 1994, Cancer treatment and research,
Copied contents to your clipboard!